# Confirmatory Study Nepafenac 0.3%

> **NCT01109173** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 2120 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** Nepafenac Ophthalmic Suspension, 0.3%
- **DRUG:** Nepafenac Ophthalmic Suspension, 0.1%
- **OTHER:** Nepafenac Ophthalmic Suspension 0.3% Vehicle
- **OTHER:** NEVANAC Vehicle

## Key facts

- **NCT ID:** NCT01109173
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 2120 (ACTUAL)
- **Last updated:** 2012-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109173, "Confirmatory Study Nepafenac 0.3%". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01109173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*